

LIST OF FIGURES

<i>Figure 1. Structure of human mature HF</i>	6
<i>Figure 2. HF growth during morphogenesis in stages 0-8</i>	8
<i>Figure 3. HF cycle.</i>	13
<i>Figure 4. Schematic presentation of the expression patterns of epithelial/hair keratins presently identified in the various HF compartments.</i>	19
<i>Figure 5. The complement classical pathway</i>	25
<i>Figure 6. Alternative pathway</i>	28
<i>Figure 7. C5 convertase</i>	28
<i>Figure 8. The membrane attack complex</i>	29
<i>Figure 9. Types of mature CD4+ T cells</i>	35
<i>Figure 10. Structure of immunoglobulin</i>	36
<i>Figure 11. Immune system regulation</i>	40
<i>Figure 12. Clinical photos of different forms of patchy AA</i>	46
<i>Figure 13. Treatment plan for AA designed by University of British Columbia and University of San Francisco</i>	59
<i>Figure 14. Simplified diagram of IgG purification using a Protein G column</i>	69
<i>Figure 15. Diagram showing an example of calculation of R_f values</i>	75
<i>Figure 16. Diagram of a simplified calibration graph</i>	76
<i>Figure 17. Analysis of IgG purified from serum N11 (a) by 1D SDS-PAGE followed by staining with SimplyBlue SafeStain (2) by 1D SDS-PAGE followed by Western blotting</i>	78
<i>Figure 18. 1D SDS-PAGE and Western Blotting of whole N13 serum and of IgG purified from N13</i>	80
<i>Figure 19. 1D SDS-PAGE and Western Blotting of 300 μg HF extract probed with IgG purified from sera</i>	81
<i>Figure 20. A diagram showing the process of HF extract pre-clearing</i>	82
<i>Figure 21. A diagram showing the steps in immunoprecipitation of target antigens in HF extract using purified serum IgG</i>	84

<i>Figure 22. Diagrammatic presentation of protein separation in two-dimensional electrophoresis</i>	85
<i>Figure 23. Diagram showing how IEF ZOOM strip is inserted into pre-cast gel during 2D gel electrophoresis</i>	87
<i>Figure 24. SimplyBlue SafeStain stained 2D electrophoresis gel of immunoprecipitate of purified IgG from serum N11 and HF extract</i>	90
<i>Figure 25. 2D gel electrophoresis followed by Western Blotting of immunoprecipitate of purified IgG from serum N11 and HF extract</i>	91
<i>Figure 26. 2D gel electrophoresis followed by Western Blotting of immunoprecipitate of purified IgG from AA11 and HF extract</i>	93
<i>Figure 27. 2D gel electrophoresis followed by Western Blotting of immunoprecipitate of purified IgG from serum AA11 and HF extract</i>	93
<i>Figure 28. A diagram showing the steps of immunoprecipitation of target antigens from HF extract by purified IgG, with cross-linking</i>	95
<i>Figure 29. An agarose gel plate for radial immunodiffusion assay, with developed antibody-antigen precipitation rings</i>	100
<i>Figure 30. 1D SDS-PAGE and Western Blotting of immunoprecipitate from (a) AA12 serum and (b) N11 serum, with HF extract</i>	103
<i>Figure 31. 2D gel electrophoresis of immunoprecipitate of AA12 serum and HF extract</i>	106
<i>Figure 32. Schematic diagram of a mass spectrometer</i>	108
<i>Figure 33. 2D gel electrophoresis of HF extract (a) transferred onto PVDF membrane for Western Blotting with AA5 and (b) stained with SimplyBlue SafeStain</i>	114
<i>Figure 34. An example of a target plate used in MALDI-TOF analysis</i>	116
<i>Figure 35. An example of the ZipTip_μ-C18 pipette tips</i>	118
<i>Figure 36 (a) to (t). Immunoprecipitation with cross-linking using serum IgG ((a) to (j) = AA1 to AA10; (k) to (t) = N1 to N10 sera) and HF extract, followed by 1D SDS-PAGE and Western Blotting</i>	133-136

<i>Figure 37. Mascot search data for AA8 sample showing 12 peptide matches for identification of THH and 1 peptide match for cyclin-dependent kinase inhibitor 1</i>	141
<i>Figure 38. Mascot search data for N3 sample showing 12 peptide matches for identification of K14 and 2 peptide matches of K32</i>	142
<i>Figure 39. Mascot search data for negative control 2 sample showing 9 peptide matches for identification of K17 and 1 for an uncharacterized protein C150rf33</i>	143
<i>Figure 40. Significance of mean Mascot score differences between AA and normal serum groups for 6 target proteins identified.</i>	146
<i>Figure 41. Isolation of HFs from human skin sample</i>	149
<i>Figure 42. Graphs showing effects of different conditions on average hair shaft elongation of 10 normal human scalp HFs at day 5 of ex vivo culture</i>	156
<i>Figure 43. Graphs showing effects of different conditions on average hair shaft elongation of 10 normal human scalp HFs from day 0 to at day 5 of ex vivo culture</i>	158
<i>Figure 44. Experiment 1 and Experiment 2. Photographs of cultured HFs at day 0 and day 5 under different culture conditions</i>	160-161
<i>Figure 45. Immunostaining of section of freshly isolated normal human scalp HF with Ki67 antibody</i>	162
<i>Figure 46. Immunostaining of sections of cultured HFs from Experiment 1 and Experiment 2, with Ki67 antibody</i>	163-166
<i>Figure 47. Detection of K16 in normal human scalp HF section by indirect immunofluorescence using an antibody to K16</i>	171
<i>Figure 48. Detection of THH in normal human scalp HF section by indirect immunofluorescence using the anti-THH antibody AE15</i>	172
<i>Figure 49. Indirect immunofluorescence analysis of antibody immunoreactivity in (a) AA sera (AA1 – AA10) (b) normal sera (N1 – N10) against antigens expressed by normal human scalp HFs</i>	173-174

<i>Figure 50. Detection of co-localisation of AA sera antibodies (a) (AA1 to AA10) (b) (N1 to N10) with anti-THH antibody AE15</i>	176-177
<i>Figure 51 (a) to (t). Detection of co-localisation of serum antibodies (AA1-AA10 and N1-N10) with anti-THH antibody</i>	178-187
<i>Figure 52. Flow chart showing the flow of experimental events from beginning to end of project</i>	193